Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
Christiaan F. Mooij, Carline E. Tacke, Mirjam E. van Albada, Winfried Barthlen, Hennie Bikker, Klaus Mohnike, Matthijs W.N. Oomen, A.S. Paul van Trotsenburg, Nitash Zwaveling-Soonawala
Ann Pediatr Endocrinol Metab. 2021;26(4):278-283.   Published online 2021 May 7     DOI:
Citations to this article as recorded by Crossref logo
A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism
Christine A. Juliana, Jinghua Chai, Pablo Arroyo, Elizabeth Rico-Bautista, Stephen F. Betz, Diva D. De León
Journal of Biological Chemistry.2023; 299(6): 104816.     CrossRef
Congenital hyperinsulinemic hypoglycemia (HH) requiring treatment as the presenting feature of Kabuki syndrome
Saloua Ait Souabni, Antoine Harvengt, Camille Legat, Philippe A. Lysy
Clinical Case Reports.2023;[Epub]     CrossRef
Pasireotide—a novel somatostatin receptor ligand after 20 years of use
Marek Bolanowski, Marcin Kałużny, Przemysław Witek, Aleksandra Jawiarczyk-Przybyłowska
Reviews in Endocrine and Metabolic Disorders.2022; 23(3): 601.     CrossRef
Multiple drugs
Reactions Weekly.2022; 1912(1): 324.     CrossRef
Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
Mirjam E. van Albada, Klaus Mohnike, Mark J. Dunne, Indi Banerjee, Stephen F. Betz
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Monogenic diabetes: recent updates on diagnosis and precision treatment: A narrative review
Kyung Mi Jang
Precision and Future Medicine.2022; 6(4): 209.     CrossRef
Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management
Dinesh Giri, Katherine Hawton, Senthil Senniappan
Journal of Pediatric Endocrinology and Metabolism.2021;[Epub]     CrossRef